RxDoctor Payments Data

Robert Territo, DO

Internal Medicine · Baton Rouge, LANPI 1871911669

Payments from drug & device makers

$644in general payments, 2019–2025

Across 30 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$208
  • Acadia Pharmaceuticals Inc$146
  • Johnson & Johnson$115
  • E.r. Squibb & Sons, L.L.C.$97
  • Pfizer$43
  • CMP Pharma, Inc.$19
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$54484%
  • Education$10016%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca8$208
Acadia Pharmaceuticals Inc6$146
Johnson & Johnson6$115
E.r. Squibb & Sons, L.L.C.6$97
Pfizer2$43
CMP Pharma, Inc.1$19
Merck1$16

How this compares

$644 in reported general payments places this provider in the 55th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$109,989
Medicare patients
389
Services billed
1,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban629$186,116
IngrezzaValbenazine Tosylate24$95,870
EntrestoSacubitril/Valsartan152$47,593
RestasisCyclosporine64$43,160
XifaxanRifaximin27$42,605
RexultiBrexpiprazole54$39,084
MyrbetriqMirabegron160$36,729
Invega SustennaPaliperidone Palmitate16$35,807
JanuviaSitagliptin Phosphate125$35,200
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc353$34,520
TrulicityDulaglutide32$28,516
TivicayDolutegravir Sodium26$28,395
JardianceEmpagliflozin92$27,899
DescovyEmtricitabine/Tenofov Alafenam11$25,042
Breo ElliptaFluticasone/Vilanterol55$23,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$186,116629 claims
Johnson & JohnsonInvega Sustenna, Xarelto$115$54,34981 claims
MerckJanuvia$16$35,200125 claims
AstraZenecaBrilinta$208$6,17528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →